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Effect of CPAP on Brachial-ankle PWV in Patients with OSAHS 2161mechanism for this effect is unclear, our finding suggests a close relationship
between OSAHS and arterial stiffness, while also reemphasizing the clinical
importance of CPAP treatment.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Obstructive sleep apnea–hypopnea syndrome (OSAHS)
is a condition characterized by repeated episodes of
partial or complete obstruction of the upper airway
during sleep, thus resulting in hypoxemia, arousal,
and fragmentation of sleep.[1,2] Individuals with
OSAHS have a higher prevalence of cardiovascular
disorders such as hypertension,[3,4] ischemic heart
disease,[5,6] stroke,[7] and arrhythmia.[8,9] Strong
evidence has identified OSAHS to be an independent
risk factor for increased cardiovascular mortality.[10]
Recent epidemiological studies have revealed that
treatment with continuous positive airway pressure
(CPAP) decreases blood pressure,[11] reduces the risk
of cardiovascular events,[12] and improves cardio-
vascular mortality in patients with OSAHS.[13] These
findings demonstrate a strong causative link be-
tween OSAHS and cardiovascular morbidity and
mortality, and CPAP treatment can reduce both of
them.
Over the past few years, arterial stiffness has
been widely investigated because it may predict
cardiovascular events beyond the classic risk
factors such as blood pressure.[14,15] In fact,
arterial stiffness increases with advancing age[16]
and other cardiovascular risk factors including a
sedentary lifestyle,[16] and hypercholesterole-
mia.[17] Among a number of parameters, arterial
pulse wave velocity (PWV) has emerged as a good
indicator of arterial stiffness.[14] PWV has been
demonstrated as an important predictor of cardi-
ovascular events in hypertensive patients.[18] A
reduction in PWV has been obtained in hyperten-
sive patients who received antihypertensive treat-
ment.[19] Of particular interest, recent studies have
revealed that PWV increases in OSAHS patients and
also correlates with apnea–hypopnea index (AHI)
which is a measure of the severity of OSAHS.[20–22]
These findings suggest a strong link between
arterial stiffness assessed by PWV and OSAHS. We,
therefore, investigated whether CPAP treatment
has any effect on arterial stiffness in patients with
OSAHS. We performed brachial-ankle PWV mea-
surements on patients with moderate to severe
OSAHS, and then compared brachial-ankle PWV
recorded during successful CPAP treatment with
that before the treatment.Materials and methods
Subjects, polysomnography, and CPAP
treatment
The present study was conducted in the respiratory
division at Hiroshima University Hospital between
April 2004 and March 2005. Informed consent was
obtained from each subject and the study protocol
was approved by the ethics committee. Seventeen
subjects (16 men and 1 woman) were enrolled. All
subjects underwent standard in-laboratory poly-
somnography using a computerized system (Alice
4s, Respironics; Pittsburgh, PA, USA). Apnea was
defined as a continuous cessation of airflow lasting
at least 10 s. Hypopnea was defined as an airflow
reduction of X50% from the baseline lasting at
least 10 s, or a less significant reduction in the
airflow accompanied by the presence of arousal or
oxygen desaturation ofX3%. AHI was calculated as
the number of apnea and hypopnea events per hour
of sleep. According to the criteria of the American
Academy of Sleep Medicine,[1] we defined moder-
ate OSAHS as 15 p AHIo30 and severe OSAHS as
AHI X30. An automated CPAP device (REMstar
Autos, Respironics), which calibrates CPAP pres-
sures automatically,[23] was applied for all patients.
Each patient visited our outpatient clinic at least
once a month and was encouraged to use the CPAP
device every night. At every visit to our hospital,
the average usage time of CPAP and AHI per night
under the CPAP treatment were calculated by the
software package included with the CPAP device
(Encore Pros, Respironics).Measurement of brachial-ankle PWV and
other variables
Brachial-ankle PWV was measured in the supine
position after 5min of bed rest using an automatic
pulse-wave velocimeter (Form PWV/ABIs, model
BP-203RPE, Colin Medical Technology Co., Komaki,
Japan).[24,25] To minimize the influence of diurnal
variation, brachial-ankle PWV was measured be-
tween 10:00 and 11:00 A.M.[26] In addition, subjects
were required to withhold meals, caffeine, and
smoking before brachial-ankle PWV measurement
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Table 1 Patient characteristics.
n ¼ 17 Mean7SEM
Age (yr) 58.672.0
Height (cm) 166.771.6
Body weight (kg) 70.972.9
Body mass index (kg/m2) 25.470.8
Smoking status (never/past/current) 7/8/2
Total cholesterol (mg/dl) 194.877.6
Heart rate (beats/min) 64.772.6
Systolic blood pressure (mmHg) 128.973.3
Diastolic blood pressure (mmHg) 80.972.4
Mean blood pressure (mmHg) 96.972.6
Y. Kitahara et al.2162to avoid any confounding influence of these factors
on arterial stiffness.[27–29] Patients who were on
anti-hypertensive medication were required to
take their drugs immediately after waking up. The
procedure for the measurement of brachial-ankle
PWV was as follows; four blood pressure cuffs were
wrapped around the bilateral brachia and ankles,
and two sensors were placed around the bilateral
wrists. Depending on the index line printed on the
pressure cuffs, we checked whether the cuff size
was appropriate for each subject. A microphone
was set on the left edge of the sternum at the
fourth intercostal space. Pulse waves and blood
pressures of brachial and tibial arteries, heart
sounds, and heart rate were recorded simulta-
neously. Blood pressures were measured by an
oscillometric method. The time lag between the
wavefront of brachial waveform and that of ankle
waveform was defined as the time interval between
the brachial and ankle pulses (DTba). The path
lengths from the suprasternal notch to the bra-
chium (Lb) and to the ankle (La) were calculated
using following equation: Lb ¼ 0.2195 height
(cm)—2.0734, La ¼ 0.8129 height (cm)+12.328.
Brachial-ankle PWV was calculated using the
following equation: brachial-ankle PWV ¼ (LaLb)/
DTba (cm/s) ¼ (LaLb)/DTba/100 (m/s).[24,25] We
measured brachial-ankle PWV at least three times,
and then selected the lowest right systolic brachial
blood pressure of the three measurements. Systolic
and diastolic brachial blood pressures, pulse pres-
sure, and brachial-ankle PWV were measured
bilaterally, and the average of the recorded values
was used for the analysis. Mean brachial blood
pressure was calculated bilaterally according to
formula: (systolic brachial blood pressurediastolic
brachial blood pressure)/3+diastolic brachial blood
pressure, and the average value was used for the
analysis. Each measurement was made before
starting CPAP, and at 2 months and 4 months after
the start of CPAP treatment. At the same time,
daytime sleepiness was evaluated using the Ep-
worth sleepiness scale (ESS), and serum total
cholesterol levels and body weight were measured.
Body mass index (BMI) was defined as the weight in
kilograms divided by the square of the height in
meters.Pulse pressure (mmHg) 48.072.1
Brachial-ankle pulse wave velocity
(m/s)
15.670.6
Epworth sleepiness scale 8.671.0
Apnea–hypopnea index (events/h) 38.574.2
Arousal index (events/h) 36.373.4
Lowest SpO2 during sleep study (%) 79.872.9
Note that data of total cholesterol were obtained
from 13 subjects.Statistical analysis
All statistical analyses were performed with the
statistical program SPSS for Windows (version 11.0;
SPSS; Chicago, IL, USA). The data are presented as
mean7SEM. The relationships between brachial-
ankle PWV and other variables were assessed usingPearson’s correlation analysis. Paired t-test was
used to compare the variables before the CPAP
treatment with those measured at 2 months and 4
months after the start of CPAP treatment. Simple
linear regression analysis was performed between
the magnitude in changes of brachial-ankle PWV
(Dbrachial-ankle PWV) and each of those in BMI
(DBMI), heart rate (Dheart rate), and systolic,
pulse, and mean blood pressures (Deach blood
pressure). A P-value of less than 0.05 was con-
sidered to be statistically significant.Results
Patient characteristics and sleep study
Characteristics of the patients are shown in Table 1.
Ages of the subjects ranged between 42 and 69
years old. Two current smokers and 8 past smokers
were included. Smoking status of the current
smokers did not change during the study period.
Mean brachial-ankle PWV was 15.670.6m/s. Mean
ESS score was 8.671.0. Based on polysomnography
results, moderate OSAHS was diagnosed in 7
patients and severe OSAHS in 10. Eleven hyperten-
sive patients, who were already taking antihyper-
tensive drugs before OSAHS was diagnosed, were
included. The antihypertensive medication for
these patients did not change during the study
period. Because recruitment of non-OSAHS subjects
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difficult to achieve, we were not able to compare
brachial-ankle PWV of the studied OSAHS patients
with that of the control subjects.
To determine whether brachial-ankle PWV was
associated with other variables, we performed
Pearson’s correlation analysis (Fig. 1 and Table 2).
Brachial-ankle PWV was found to positively corre-
late with arousal index (Fig. 1c; r ¼ 0.596,
P ¼ 0.012) but not with maximal desaturation from
the baseline (Fig. 1e; r ¼ 0.371, P ¼ 0.143), the
lowest percutaneous arterial saturation (SpO2)
during sleep study (Fig. 1f; r ¼ 0.323,
P ¼ 0.206). Brachial-ankle PWV tended to increase
with an increasing ESS score (Fig. 1a; r ¼ 0.464,
P ¼ 0.061), AHI (Fig. 1b; r ¼ 0.478, P ¼ 0.053), and
desaturation index, the number of desaturation
episodes (drop in SpO2 X3% from the baseline) per
hour of sleep (Fig. 1d; r ¼ 0.419, P ¼ 0.094), but
these correlations were not statistically significant.
As shown in Table 2, brachial-ankle PWV was found
to positively correlate with heart rate (r ¼ 0.510,
P ¼ 0.036), systolic blood pressure (r ¼ 0.678, P ¼
0.003), diastolic blood pressure (r ¼ 0.603, P ¼
0.010), mean blood pressure (r ¼ 0.670, P ¼B
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Fig. 1 Relationships between brachial-ankle pulse wave velo
sleep data. Brachial-ankle PWV was found to positively corre
with maximal desaturation from the baseline (e; r ¼ 0.371, P
(SpO2) during sleep study (f; r ¼ 0.323, P ¼ 0.206). Brachi
score (Fig. 1a; r ¼ 0.464, P ¼ 0.061), apnea–hypopnea index
(d; r ¼ 0.419, P ¼ 0.094), but these correlations were not st0.003), but not with BMI (r ¼ 0.029, P ¼ 0.912),
serum total cholesterol levels (n ¼ 13, r ¼ 0.459,
P ¼ 0.115), or pulse pressure (r ¼ 0.366,
P ¼ 0.148).Effect of CPAP treatment
Based on the recorded data on CPAP usage and AHI,
we confirmed that all patients utilized CPAP
appropriately and the treatment was successful
(the first 2 months: CPAP usage time, 295.27
17.1min/night, AHI, 3.970.7 events/h; the last 2
months: CPAP usage time, 331.5720.8min/night,
AHI, 3.170.5 events/h).
We first intended to see whether the association
of brachial-ankle PWV with other variables changed
at 2 months and 4 months after the start of CPAP
(Table 2). Systolic blood pressure, mean blood
pressure, and pulse pressure were significantly
correlated with brachial-ankle PWV at both 2 and
4 months after the start of CPAP. The data obtained
from 13 patients showed that serum total choles-
terol levels also significantly correlated with
brachial-ankle PWV at both 2 and 4 months afterArousal index
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al-ankle PWV tended to increase with an increasing ESS
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atistically significant.
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Table 2 Correlation between brachial-ankle PMV and other variables before, and at 2 months, and 4 months
after the start of CPAP.
Correlation between brachial-ankle PWW
Mean7SEM r P
Body mass index (kg/m2)
Baseline 25.470.8 0.029 0.912
2 months after 25.570.8 0.041 0.876
4 months after 25.770.8 0.235 0.364
Total cholesterol (mg/dl, n ¼ 13)
Baseline 194.877.6 0.459 0.115
2 months after 192.276.4 0.565 0.044y
4 months after 199.279.8 0.74 0.004y
Heart rate (beats/min)
Baseline 64.772.6 0.51 0.036y
2 months after 63.872.6 0.528 0.029y
4 months after 64.272.8 0.305 0.234
Systolic blood pressure (mmHg)
Baseline 128.973.3 0.678 0.003y
2 months after 127.674.1 0.683 0.003y
4 months after 132.673.6 0.706 0.002y
Diastolic blood pressure (mmHg)
Baseline 80.972.4 0.603 0.010y
2 months after 79.672.4 0.514 0.035y
4 months after 80.972.6 0.459 0.064
Mean blood pressure (mmHg)
Baseline 96.972.6 0.67 0.003y
2 months after 95.672.9 0.616 0.008y
4 months after 98.172.7 0.607 0.010y
Pulse pressure (mmHg)
Baseline 48.072.1 0.366 0.148
2 months after 47.972.4 0.631 0.007y
4 months after 51.872.6 0.537 0.026y
yPo0.05.
Y. Kitahara et al.2164the start of CPAP. Heart rate and diastolic blood
pressure significantly correlated with brachial-
ankle PWV at 2 months after the start of CPAP.
We then analyzed the influence of CPAP on heart
rate, systolic and diastolic blood pressures, mean
blood pressure, pulse pressure, BMI, total choles-
terol and ESS as well as brachial-ankle PWV (Figs. 2
and 3). The CPAP treatment did not have any
significant effect on heart rate (Fig. 2a; P ¼ 0.518
at 2 months after the start of CPAP, and P ¼ 0.711
at 4 months after the start of CPAP), systolic blood
pressure (Fig. 2b; P ¼ 0.523 at 2 months after the
start of CPAP, and P ¼ 0.150 at 4 months after the
start of CPAP), diastolic blood pressure (Fig. 2c;
P ¼ 0.491 at 2 months after the start of CPAP, and
P ¼ 0.985 at 4 months after the start of CPAP),
mean blood pressure (Fig. 2d; P ¼ 0.471 at 2
months after the start of CPAP, and P ¼ 0.461 at 4
months after the start of CPAP), pulse pressure
(Fig. 2e; P ¼ 0.968 at 2 months after the start ofCPAP, and P ¼ 0.057 at 4 months after the start of
CPAP) and serum total cholesterol levels (Fig. 3b;
n ¼ 13, P ¼ 0.643 at 2 months after the start of
CPAP, and P ¼ 0.554 at 4 months after the start of
CPAP). However, the CPAP treatment significantly
improved ESS score (Fig. 3c; 5.370.7 at 4 months
after the start of CPAP, P ¼ 0.001) and it effectively
decreased brachial-ankle PWV (Fig. 3d;
15.070.5m/s at 2 months after the start of CPAP,
P ¼ 0.010; 14.970.6m/s at 4 months after the
start of CPAP, P ¼ 0.027). BMI significantly in-
creased from 2 months to 4 months after the start
of CPAP (Fig. 3a; 25.570.8 kg/m2 at 2 months after
the start of CPAP and 25.770.8 kg/m2 at 4 months
after the start of CPAP, P ¼ 0.036).
Next, using simple linear regression analysis, we
intended to determine whether the magnitude of
changes in brachial-ankle PWV (Dbrachial-ankle
PWV) was correlated with each of those in BMI,
heart rate, and systolic, pulse, and mean blood
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Fig. 2 Effect of continuous positive airway pressure (CPAP) treatment on heart rate (a), systolic blood pressure (b),
diastolic blood pressure (c), mean blood pressure (d), and pulse pressure (e). The CPAP treatment did not have a
significant effect on heart rate (a; P ¼ 0.518 at 2 months after the start of CPAP, and P ¼ 0.711 at 4 months after the
start of CPAP), systolic blood pressure (b; P ¼ 0.523 at 2 months after the start of CPAP, and P ¼ 0.150 at 4 months after
the start of CPAP), diastolic blood pressure (c; P ¼ 0.491 at 2 months after the start of CPAP, and P ¼ 0.985 at 4 months
after the start of CPAP), mean blood pressure (d; P ¼ 0.471 at 2 months after the start of CPAP start, and P ¼ 0.461 at 4
months after the start of CPAP), pulse pressure (e; P ¼ 0.968 at 2 months after the start of CPAP, and P ¼ 0.057 at 4
months after the start of CPAP).
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affect PWV.[14,30–32] As shown in Table 3, Dbrachial-
ankle PWV was found not significantly associated
with each other variable.Discussion
OSAHS is recognized as an independent risk factor for
cardiovascular disorders such as hypertension,[3,4]
ischemic heart disease,[5,6] stroke,[7] and arrhyth-
mia,[8,9] and is strongly associated with cardiovascu-
lar morbidity and mortality.[10,12,13] Arterial stiffness
is another cardiovascular risk factor which is believed
to predict cardiovascular events better than classic
risk factors such as blood pressure.[14,15] Brachial-
ankle PWV is a newly introduced parameter which
represents the degree of arterial stiffness with good
sensitivity and reproducibility.[25] The correlation of
brachial-ankle PWV with aortic PWV and carotid-
femoral PWV, both of which are established indices to
represent aortic stiffness and predict cardiovascular
mortality, has been repeatedly demonstrated.[24,25,33]In the present study, we found CPAP treatment to
decrease brachial-ankle PWV in patients with
moderate to severe OSAHS. However, serum total
cholesterol levels, heart rate, systolic and diastolic
blood pressures, mean blood pressure, and pulse
pressure in the studied patients did not differ
before and after CPAP treatment. The decrease in
brachial-ankle PWV was considered to be indepen-
dent of these factors which affect PWV. Previous
studies have demonstrated the effects of CPAP
treatment to reduce blood pressure in OSAHS
patients.[11,34,35] However, some studies have failed
to show any beneficial effects in the reductions of
daytime blood pressure.[36,37] CPAP treatment was
also shown not to affect blood pressure in normo-
tensive OSAHS patients.[38] In addition, a recent
study has shown that automated CPAP treatment
does not acutely change systolic and diastolic blood
pressures.[39] Considering the fact that that day-
time blood pressures in the studied hypertensive
patients were well controlled by optimal antihy-
pertensive medication, the failure of the success-
ful automated CPAP treatment to reduce blood
ARTICLE IN PRESS
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Fig. 3 Effect of continuous positive airway pressure (CPAP) treatment on body mass index (BMI) (a), serum total
cholesterol levels (b), Epworth sleepiness scale (ESS) score (c), and brachial-ankle pulse wave velocity (PWV) (d). BMI
significantly increased from 2 months to 4 months after the start of CPAP (a; 25.570.8 kg/m2 at 2 months after the start
of CPAP start and 25.770.8 kg/m2 after 4 months after the start of CPAP, P ¼ 0.036). Serum total cholesterol levels did
not change before and after CPAP treatment (b; n ¼ 13, P ¼ 0.643 at 2 months after the start of CPAP, and P ¼ 0.554 at
4 months after the start of CPAP). However, the CPAP treatment significantly improved ESS score (c; 5.370.7 at 4
months after the start of CPAP, P ¼ 0.001) and it effectively decreased brachial-ankle PWV as shown (d; 15.070.5m/s
at 2 months after the start of CPAP, P ¼ 0.010; 14.970.6m/s at 4 months after the start of CPAP, P ¼ 0.027).
Table 3 Simple linear regression analysis on the
magnitude of changes in brachial-ankle PWV (D
brachial-ankle PWV) versus each of those in other
variables (D each variable).
D variable b P R2
Baseline to 2 months
D body mass index 0.230 0.375 0.053
D heart rate 0.314 0.219 0.099
D systolic blood pressure 0.248 0.338 0.061
D mean blood pressure 0.152 0.560 0.023
D pulse pressure 0.242 0.350 0.058
2 months to 4 months
D body mass index 0.007 0.978 o0.001
D heart rate 0.229 0.377 0.052
D systolic blood pressure 0.431 0.084 0.186
D mean blood pressure 0.423 0.091 0.179
D pulse pressure 0.265 0.304 0.070
b ¼ standardized regression coefficient.
Y. Kitahara et al.2166pressure is considered to be consistent with these
previous observations.
We demonstrated brachial-ankle PWV to be
significantly correlated with systolic blood pres-
sure, mean blood pressure, and pulse pressure at
both 2 and 4 months after the start of CPAP, thus
suggesting that these blood pressures were still
major associated factors of brachial-ankle PWV
even after the CPAP treatment decreased it.[14]
However, we also found that the magnitudes of
changes in brachial-ankle PWV from the baseline to
2 months and from 2 to 4 months after the start of
CPAP did not correlate with each of those in
systolic, pulse, and mean blood pressures. In
addition, the magnitude of changes in brachial-
ankle PWV was found not significantly associated
with that in BMI nor heart rate. These observations
support our conclusion that CPAP treatment de-
creased brachial-ankle PWV independently of the
ARTICLE IN PRESS
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sures, all of which have been reported to affect
PWV.[14,30–32]
The mechanism by which CPAP treatment de-
creased brachial-ankle PWV in OSAHS patients was
not determined in the present study. A number of
factors may be involved in this process. Repetitive
apnea–hypopnea events during sleep are reported
to induce sympathetic nerve activity,[36,40] an
impaired artery endothelial function,[41,42] reduced
nitric oxide derivatives,[43] increased systemic
inflammation,[44] and elevated plasma endothelin-
1 levels,[45] all of which are associated with the
regulation of vascular tone and elasticity. Among
them, endothelin-1 is thought to be important
because it is reported to regulate PWV in vivo.[46]
Of particular interest, CPAP treatment is shown to
blunt all of these changes in less than 1
month.[40,41,43–45] We showed in the present study
that CPAP treatment decreased brachial-ankle PWV
as soon as 2 months after its start. Given that this
result was thereafter consistently observed, the
CPAP treatment may thus have rapidly normalized
some or all factors listed above, thereby causing a
decrease in brachial-ankle PWV demonstrated in
OSAHS patients. Particularly, among these possibi-
lities, we speculate that a reduction in the
sympathetic nerve activity by CPAP treatment is
the most likely explanation for the decrease in
brachial-ankle PWV in OSAHS patients. PWV is a
reflection of both a central elastic component and
a peripheral muscular component. Compared with
carotid-femoral PWV, brachial-ankle PWV is af-
fected more strongly by the peripheral muscular
component, and in comparison to aortic stiffness,
the stiffness of the muscular arteries is more
strongly regulated by the sympathetic nerve sys-
tem. In fact, a recent study has demonstrated
brachial-ankle PWV to be closely associated with
the sympathetic nerve activity in young Japanese
men.[47] This finding also supports our speculation
raised above.
The present study was carried out at a general
outpatient clinic. Mainly for ethical reasons, we
were not able to randomize OSAHS patients into a
group to be treated with sham CPAP. In addition,
because the recruitment of non-OSAHS subjects
matched for age and hypertensive profile was
difficult to achieve, we were not able to evaluate
whether brachial-ankle PWV increased in OSAHS
patients in comparison to control subjects, and the
independent role played by OSAHS in increasing
brachial-ankle PWV could not be determined. To
minimize the confounding influences on PWV such
as diurnal variation, meals and coffee intake, and
smoking, brachial-ankle PWV was measured in thefasted and smoking-free state between 10:00 to
11:00 A.M.[26] Although we showed that success-
ful CPAP treatment decreased brachial-ankle
PWV without affecting blood pressures, further
studies with adequately control for confounders by
including a matched control group or a sham CPAP
group are warranted to provide more convincing
evidence.
PWV has been demonstrated to have a close
association with all-cause mortality and cardiovas-
cular mortality in patients with hypertension, type
2 diabetes, and end-stage renal disease.[18,48,49]
For example, in patients with end-stage renal
disease, aortic PWV49.4m/s was an independent
predictor of all-cause and cardiovascular mortality.
In this population, relative risk of all-cause mor-
tality was 1.39 (95% confidence interval [CI],
1.19–1.62) for each PWV increase of 1m/s.[48] In
patients with type 2 diabetes, aortic PWV indepen-
dently predicted all cause and cardiovascular
mortality for each 1m/s increase (hazard ratio,
1.08; 95% CI, 1.03–1.14).[49] If these findings are
applicable to the OSAHS patients in the present
study, then the effect of CPAP treatment to
decrease brachial-ankle PWV should have clinical
significance in reducing all-cause and cardiovascu-
lar mortality.
In conclusion, we have shown that CPAP treat-
ment substantially decreases brachial-ankle PWV in
OSAHS patients without reducing blood pressures in
a non-randomized and uncontrolled study. To our
knowledge, this is the first report to demonstrate
an association between PWV and CPAP treatment in
OSAHS patients. The precise mechanism for this
CPAP effect is unclear; however, this finding
suggests a close relationship between OSAHS and
arterial stiffness, while also reemphasizing the
clinical importance of CPAP treatment.Acknowledgments
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